IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
Aug 17, 2023
Register for an engaging webinar led by Naz Chaudary, Ph.D., and Research Technician, Alex Wang from the...
Optimizing Gene Expression with Bioluminescence & the piggyBac System
Aug 15, 2023
Discover how bioluminescence imaging & the piggyBac gene editing system optimize & track gene expression in mouse...
High-plex immunofluorescence imaging and traditional histology of the same tissue section
Aug 7, 2023
RareCyte Orion’ platform has been used for collecting H&E and high-plex immunofluorescence images from the same cells...
Drive key insights and discoveries with NEW Live Cell Analysis applications for eSight system
Aug 2, 2023
eSight is now powerful like never before. Learn more about new dedicated application modules for live-cell analysis: 3D...
Single cell-resolution in situ sequencing elucidates spatial dynamics of multiple sclerosis
Jul 14, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, fluidics, image processing,...
High speed, compact and fully automated microscope inside your incubator? Lumascope850
Jul 13, 2023
The powerful, new LS850 Microscope is the latest generation of our fully automated three-channel flagship model and...
MARS - High Efficiency Separation of CD34+ HSC from Mobilized Blood
Jul 12, 2023
MARS platform provides an easy and cost-effective protocol for CD34+ cell isolation. Single pass CD34+ HSC enrichment...
43 markers, ONE tube : Impress yourself with Cytek Aurora Spectral Cytometer
Jul 11, 2023
Using Cytek full spectrum flow cytometry, scientists at Hamad Medical Corporation, developed a 43 color panel to...
Better antibody discovery using IntelliCyt’s iQue Screener
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Related technologies: HTP Screening
Get more info
Brand profile
